Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy

Abstract excerpt

The advent of the covalent Bruton’s tyrosine kinase (BTK) inhibitors ibrutinib, acalabrutinib, and zanubrutinib has markedly improved outcomes for patients with advanced chronic lymphocytic leukaemia (CLL), yielding high response rates and durable remissions. However, resistance—predominantly driven by Cys481 mutations—and adverse events, including cardiac arrhythmias and infections, limit their long-term benefit....

Topics

Open a Topic to create a Post that cites this publication.

• Agammaglobulinaemia Tyrosine Kinase
• Chronic Lymphocytic Leukemia Research
• Drug Resistance, Neoplasm
• Leukemia, Lymphocytic, Chronic, B-Cell
• Molecular Targeted Therapy
• Piperidines
• Protein Kinase Inhibitors
• Receptors, Antigen, B-Cell

Identifiers and source

Literature Corpus work

8ae9038a-955e-57eb-9869-368cb506fa4a

DOI

10.20944/preprints202508.1373.v1